1
|
Vanorio-Vega I, Constantinou P, Bret V, Gentile S, Finne P, Sautenet B, Tuppin P, Couchoud C. Effect of comorbidities on healthcare expenditures for patients on kidney replacement therapy considering the treatment modality and duration in a French cohort. Eur J Health Econ 2024; 25:269-279. [PMID: 37004630 DOI: 10.1007/s10198-023-01585-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Accepted: 03/16/2023] [Indexed: 06/19/2023]
Abstract
End-stage kidney disease (ESKD) is associated with a substantial economic burden. In France, the cost of care for such patients represents 2.5% of the total French healthcare expenditures but serves less than 1% of the population. These patients' healthcare expenditures are high because of the specialized and complex treatment needed as well as the presence of multiple comorbidities. This study aims to describe and assess the effect of comorbidities on healthcare expenditures (direct medical cost and non-medical costs including transportation and compensatory allowances) for patients with ESKD in France while considering the modality and duration of renal replacement therapy (RRT). This study included adults who started RRT for the first time between 2012 and 2014 in France and were followed for 5 years. Generalized linear models were built to predict mean monthly cost (MMC) by integrating first the time duration in the cohort, then patient characteristics and finally the duration of use of each treatment modalities. Comorbidities with the highest effect on MMC were inability to walk (+ 1435€), active cancer (+ 593€), HIV positivity (+ 507€) and diabetes (+ 396€). These effects vary according to age or treatment modalities. This study confirms the importance of considering patient characteristics, comorbidities and type of RRT when assessing healthcare expenditures for patients with ESKD.
Collapse
Affiliation(s)
- Isabella Vanorio-Vega
- Direction de la Stratégie des Études et des Statistiques, Caisse Nationale de L'assurance Maladie (CNAM), 75986, Paris, France.
- Agence de la Biomédecine, 1 Avenue du Stade de France, 93212, Saint-Denis, France.
| | - Panayotis Constantinou
- Direction de la Stratégie des Études et des Statistiques, Caisse Nationale de L'assurance Maladie (CNAM), 75986, Paris, France
| | - Victor Bret
- Direction de la Stratégie des Études et des Statistiques, Caisse Nationale de L'assurance Maladie (CNAM), 75986, Paris, France
| | - Stéphanie Gentile
- School of Medicine-La Timone Medical Campus, EA 3279: CEReSS-Health Service Research and Quality of Life Center, Aix Marseille University, Marseille, France
| | - Patrik Finne
- Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - Bénédicte Sautenet
- MCU-PH Service Néphrologie-Hypertension Artérielle, Dialyses, Transplantation Rénale INSERM U1246 SPHERE, Nantes, France
| | - Philippe Tuppin
- Direction de la Stratégie des Études et des Statistiques, Caisse Nationale de L'assurance Maladie (CNAM), 75986, Paris, France
| | - Cécile Couchoud
- Agence de la Biomédecine, 1 Avenue du Stade de France, 93212, Saint-Denis, France
| |
Collapse
|
2
|
Mroué A, Roueff S, Vanorio-Vega I, Lazareth H, Kovalska O, Flahault A, Tuppin P, Thervet E, Iliou MC. Benefits of Cardiac Rehabilitation in Cardio-Renal Patients With Heart Failure With Reduced Ejection Fraction. J Cardiopulm Rehabil Prev 2023; 43:444-452. [PMID: 36892848 DOI: 10.1097/hcr.0000000000000781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/10/2023]
Abstract
PURPOSE Chronic kidney disease (CKD) is common in heart failure (HF). Chronic kidney disease often worsens the prognosis and impairs the management of patients with HF. Chronic kidney disease is frequently accompanied by sarcopenia, which limits the benefits of cardiac rehabilitation (CR). The aim of this study was to evaluate the impact of CR on cardiorespiratory fitness in HF patients with reduced ejection fraction (HFrEF) according to the CKD stage. METHODS We conducted a retrospective study including 567 consecutive patients with HFrEF, who underwent a 4-wk CR program, and who were evaluated by cardiorespiratory exercise test before and after the program. Patients were stratified according to their estimated glomerular filtration rate (eGFR). We performed multivariate analysis looking for factors associated with an improvement of 10% in peak oxygen uptake (V˙ o2peak ). RESULTS Thirty-eight percent of patients had eGFR <60 mL/min/1.73m². With decreasing eGFR, we observed deterioration in V˙ o2peak , first ventilatory threshold (VT1) and workload and an increase in brain natriuretic peptide levels at baseline. After CR, there was an improvement in V˙ O2peak (15.3 vs 17.8 mL/kg/min, P < .001), VT1 (10.5 vs 12.4 mL/kg/min, P < .001), workload (77 vs 94 W, P < .001), and brain natriuretic peptide (688 vs 488 pg/mL, P < .001). These improvements were statistically significant for all stages of CKD. In a multivariate analysis predicting factors associated with V˙ o2peak improvement, renal function did not interfere with results. CONCLUSIONS Cardiac rehabilitation is beneficial in patients with HFrEF with CKD regardless of CKD stage. The presence of CKD should not prevent the prescription of CR in patients with HFrEF.
Collapse
Affiliation(s)
- Ahmad Mroué
- Department of Nephrology, Georges Pompidou European Hospital, APHP, Paris, France (Drs Mroué, Roueff, Lazareth, Flahault, and Thervet); Direction de la stratégie des études et des statistiques, Caisse nationale de l'assurance maladie (CNAM), Paris, France (Drs Vanorio-Vega and Tuppin); Agence de la biomédecine, Saint-Denis, France (Dr Vanorio-Vega); Université Paris Cité, Paris, France (Drs Lazareth, Flahault, and Thervet); and Department of Cardiac Rehabilitation and Secondary Prevention, Corentin Celton Hospital, APHP, Paris, France (Drs Kovalska and Iliou)
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Vanorio-Vega I, Constantinou P, Hami A, Cellarier E, Rachas A, Tuppin P, Couchoud C. Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease. BMC Health Serv Res 2023; 23:1140. [PMID: 37872574 PMCID: PMC10594771 DOI: 10.1186/s12913-023-10145-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 10/14/2023] [Indexed: 10/25/2023] Open
Abstract
BACKGROUND The use of national medico-administrative databases for epidemiological studies has increased in the last decades. In France, the Healthcare Expenditures and Conditions Mapping (HECM) algorithm has been developed to analyse and monitor the morbidity and economic burden of 58 diseases. We aimed to assess the performance of the HECM in identifying different conditions in patients with end-stage kidney disease (ESKD) using data from the REIN registry (the French National Registry for patients with ESKD). METHODS We included all patients over 18 years of age who started renal replacement therapy in France in 2018. Five conditions with a similar definition in both databases were included (ESKD, diabetes, human immunodeficiency virus [HIV], coronary insufficiency, and cancer). The performance of each SNDS algorithm was assessed using sensitivity, specificity, positive predictive values (PPVs), negative predictive values (NPVs), and Cohen's kappa coefficient. RESULTS In total 5,971 patients were included. Among them, 81% were identified as having ESKD in both databases. Diabetes was the condition with the best performance, with a sensitivity, specificity, PPV, NPV, and Kappa coefficient all over 80%. Cancer had the lowest level of agreement with a Kappa coefficient of 51% and a high specificity and high NPV (94% and 95%). The conditions for which the definition in the HECM included disease-specific medications performed better in our study. CONCLUSION The HECM showed good to very good concordance with the REIN database information overall, with the exception of cancer. Further validation of the HECM tool in other populations should be performed.
Collapse
Affiliation(s)
- Isabella Vanorio-Vega
- Direction de La Stratégie Des Études Et Des Statistiques, Caisse Nationale de L’assurance Maladie (CNAM), Paris, Cedex 20 75986 France
- Agence de La Biomédecine, 1 Avenue du Stade de France, Saint-Denis, 93212 France
| | - Panayotis Constantinou
- Direction de La Stratégie Des Études Et Des Statistiques, Caisse Nationale de L’assurance Maladie (CNAM), Paris, Cedex 20 75986 France
| | - Assia Hami
- Centre Hospitalier Universitaire de Nantes. PHU1-Institut de Transplantation Urologie Néphrologie (ITUN), Centre d’Hemodialyse Chronique- Aile Nord-Zone Administrative RCB, Nantes, France
| | - Eric Cellarier
- Centre Hospitalier Universitaire Clermont-Ferrand, Hôpital Gabriel Montpied Département d’Information Médicale, Clermont-Ferrand, 63003 France
| | - Antoine Rachas
- Direction de La Stratégie Des Études Et Des Statistiques, Caisse Nationale de L’assurance Maladie (CNAM), Paris, Cedex 20 75986 France
| | - Philippe Tuppin
- Direction de La Stratégie Des Études Et Des Statistiques, Caisse Nationale de L’assurance Maladie (CNAM), Paris, Cedex 20 75986 France
| | - Cécile Couchoud
- Agence de La Biomédecine, 1 Avenue du Stade de France, Saint-Denis, 93212 France
| |
Collapse
|
4
|
Laruelle E, Huré F, Dolley-Hitze T, Vanorio-Vega I, Bayat S, Couchoud C. Home Dialysis Does Not Have the Monopoly on Low Cost. Kidney Int Rep 2022; 8:188-196. [PMID: 36644358 PMCID: PMC9831933 DOI: 10.1016/j.ekir.2022.10.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Revised: 10/17/2022] [Accepted: 10/18/2022] [Indexed: 11/13/2022] Open
Affiliation(s)
- Eric Laruelle
- Association des Urémiques chroniques de Bretagne Sante Dialyse, Rennes, France
- Service de Néphrologie, Centre Hospitalo-Universitaire Rennes, Rennes, France
| | - Fabrice Huré
- Association des Urémiques chroniques de Bretagne Sante Dialyse, Rennes, France
| | | | - Isabella Vanorio-Vega
- Réseau Epidémiologie et Information en Néphrologie Registry, Agence de la biomédecine, Saint-Denis La Plaine, France
- Caisse nationale de l’assurance maladie, Direction de la stratégie des études et des statistiques, Paris Cedex, France
| | - Sahar Bayat
- Universite de Rennes, Ecole des Hautes Etudes en Santé Publique, REPERES (Recherche en pharmaco-épidémiologie et recours aux soins), EA, Rennes, France
| | - Cécile Couchoud
- Réseau Epidémiologie et Information en Néphrologie Registry, Agence de la biomédecine, Saint-Denis La Plaine, France
- Correspondence: Cécile Couchoud, Coordination nationale de Réseau Epidémiologie et Information en Néphrologie, Agence de la biomédecine, 1 avenue du Stade de, Saint-Denis La Plaine Cedex 93212, France.
| | | |
Collapse
|
5
|
Dolley-Hitze T, Couchoud C, Huré F, Vanorio-Vega I, Bayat S, Laruelle E. La dialyse à domicile n’a pas le monopole des coûts bas en dialyse. Nephrol Ther 2022. [DOI: 10.1016/j.nephro.2022.07.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Vanorio-Vega I, Constantinou P, Tuppin P, Couchoud C. Additional cost of end-stage kidney disease in diabetic patients according to renal replacement therapy modality: a systematic review. Ren Replace Ther 2021. [DOI: 10.1186/s41100-021-00346-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
AbstractThe prevalence of end-stage kidney disease (ESKD) is growing worldwide; the survival of these patients requires renal replacement therapy (RRT, a complex and costly treatment). Over 20% of the patients that start RTT had diabetes. Limited evidence on the effect of comorbidities on the cost of RRT exists. This review summarizes the available evidence on the effect of diabetes mellitus (DM) on the cost of RRT. Electronic databases were searched using key words that combined RRT with DM and cost. References were identified with title, abstract, and full-text screening. The studies included were published in English and presented data on the cost of RRT in ESKD patients with comparison between DM status. Seventeen studies were included in this review. The crude and adjusted cost of care estimates for patients on dialysis was generally higher for DM patients. The cost of care of ESKD patients differed according to various treatment modalities and these differences, mainly driven by inpatient costs. Overall, we found an increased cost of RRT care in patients with DM regardless of the type of treatment. Future analysis of the effects of multiple comorbidities should be considered to better understand the effect of DM on the cost of RRT.
Collapse
|